Finally, a medication that will lower blood sugar levels for the people who have type two diabetes. The new medication decreases the risk of kidney disease as well as cardiovascular disease. About 450 million people around the whole world have a diagnosis of type two diabetes. That’s why the study done by The George Institute for Global Health is so important. The findings after the study were then published in the New England Journal of Medicine stating that the new drug canagliflozin can decrease cardiovascular disease by fourteen percent as well as reducing renal disease significantly. Canagliflozin will also reduce heart failure caused by hospitalization by thirty-three percent.
Bruce Neal, a local professor at the George Institute for Global Health, says the research findings were shared with the American Diabetes Associations Conference in California. At the conference in San Diego California, the American Association were very exciting for the thousands of being suffering from type two diabetes, and they were very hopefully for everyone with this disease. For the people who have type two diabetes the most common reason of death is coronary heart disease.
With canagliflozin medication, it will ensure people suffering from type two diabetes some real hope of reducing the chance of death due to heart disease, and it also has plenty of benefits. Did you more than half of the people with type two diabetes are overweight, and with canagliflozin, it will help with weight loss as well as lowering their blood pressure.
New Medication Brings On Great Results
Experts are saying that type two diabetes is only increasing throughout the whole world. People need to do something about it now. There needs to be more medications like canagliflozin that will keep their blood sugars controlled. Having more medication like canagliflozin will only benefit people with type two diabetes. It helps to their high blood pressure, being overweight, low blood circulation and more because . It lowers their risks of heart attacks and strokes.
The review is especially essential to those in Australia. Around sixty-five percent of every single cardiovascular passing happen in people with diabetes or pre-diabetes.
Professor Vlado Perkovic, Executive Director of The George Institute Australia, stated that patients and doctors ought to be happy about the outcomes. It not only decreases the danger of coronary illness, but it also helps prevent kidney disease.
Canagliflozin is a SGLT2 inhibitor. It is a moderately new kind of medication that works by hindering the body’s re-absorption of sugar or glucose. Most different diabetes drugs work by overseeing insulin levels.